Oxycontin

A plaintiffs group in Washington, D.C., has filed a $5.2 billion lawsuit against Purdue Pharma LP and Abbott Laboratories Inc. charging the drug companies with allegedly failing to warn patients the painkiller OxyContin is dangerously addictive.

The suit was filed by seven people who are former addicts or relatives of addicts, the suit charges the companies with aggressively marketing the drug without warning of the risks. The plaintiffs are also seeking class action status.

Stamford, Connecticut-based Purdue manufactures OxyContin, while Abbott co-markets the drug, a painkiller intended for use by terminal cancer patients and chronic pain sufferers. Allegations have surfaced that the drug has been linked to numerous deaths.

Purdue in May said it had met with officials from the federal Drug Enforcement Administration because of the agency's concerns about its illegal diversion and abuse. Purdue Pharma around the same time said it tried to reduce abuse of the prescription drug through several actions including halting distribution of the drug in 160 mg tablets, its highest-strength dosage.

.According to the lawsuit, defendants ``made misrepresentations or failed to adequately and sufficiently warn individuals regarding the appropriate uses, risks and safety of OxyContin.'' It contends OxyContin's sales, which exceeded $1 billion in the United States in 2000, were the result of an ``aggressive marketing strategy'' to physicians, pharmacists and patients that, ``misrepresented the appropriate uses of OxyContin and failed to adequately disclose and discuss the safety issues and possible adverse effects of OxyContin use.''

Specifically, the suit quotes a May 2000 U.S. Food and Drug Administration warning letter to Purdue Pharma ordering the company to cease use of an advertisement for the drug that appeared in a medical journal. The suit quotes a section from the warning letter that suggests the advertisement inaccurately represents the drug as a first-line treatment for osteoarthritis. ``As a result of drug company defendants' inappropriate marketing of OxyContin, the drug has been inappropriately prescribed and used, unnecessarily putting people at risk of addiction to OxyContin,'' the suit alleges.

Contact us  if you believe you may have a claim for damages. Remember to leave your phone number if you wish to be contacted by telephone.

< BACK

If you feel as though you have been injured by a defective pharmaceutical product contact us.
Free claim evaluation. 1-800-318-LAW1


PRESCRIPTION DRUG QUESTIONS & ANSWERS

- Arava FAQs
- Meridia FAQs
- Prempro FAQs
- Vioxx FAQs

At Munley, Munley & Cartwright, our goal is to provide exceptional legal services to our clients. We strive to achieve the highest standard of excellence for the protection of individual rights through team work and the use of our considerable resources and experience. For a free consultation regarding your legal concerns, contact us today for a free consultation or call us toll free at 1-800-318-LAW1.